PWA
NVIV

Provenance Wealth Advisors’s InVivo Therapeutics Holdings Corp NVIV Stock Holding History

Provenance Wealth Advisors’s Portfolio NVIV Stock Details NVIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1
Closed -$1 – 634
2023
Q4 		$1 Hold
1
– – ﹤0.01% 596
2023
Q3 		$1 Buy
+1
New +$1 ﹤0.01% 485

Other funds holding NVIV

Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
VL
Vima LLC Troy, Michigan $103M AUM

Provenance Wealth Advisors's NVIV Position: Q1 2024 in Review

Provenance Wealth Advisors sold out of InVivo Therapeutics Holdings Corp (NVIV) in Q1 2024, closing a stake of 1 share — an estimated $1 sold.

Provenance Wealth Advisors first reported a position in NVIV in Q3 2023 and held it in 2 quarters. The position peaked at $1 in Q4 2023. 4 funds tracked by Wall St. Rank hold NVIV as of Q1 2024.

  • Provenance Wealth Advisors reported no remaining InVivo Therapeutics Holdings Corp position as of Q1 2024 after selling out during the quarter.
  • Provenance Wealth Advisors sold 1 InVivo Therapeutics Holdings Corp share in Q1 2024, an estimated $1.
  • Provenance Wealth Advisors first reported a position in InVivo Therapeutics Holdings Corp in Q3 2023 and held it in 2 quarters.
  • Provenance Wealth Advisors's InVivo Therapeutics Holdings Corp position peaked at $1 in Q4 2023.
  • 4 funds tracked by Wall St. Rank held InVivo Therapeutics Holdings Corp as of Q1 2024.

Based on Provenance Wealth Advisors's 13F filing for Q1 2024, filed 15 Aug 2025.